UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results - Q4 revenue of $32.2 million - Q4 gross profit increased 9% year-over-year to $24.1 million - Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively - Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

#OPRX UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/OPRX/update-optimiz...

OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results - Q4 revenue of $32.2 million - Q4 gross profit increased 9% year-over-year to $24.1 million - Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively - Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

#OPRX OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/OPRX/optimize-rx-re...

Whetstone Dumps 79,000 monday.com Shares Worth $15.3 Million | The Motley Fool This cloud-based software provider serves organizations worldwide with modular tools for work management and collaboration.

#MNDY #DAVE #NET #GOOGL #AMZN #OPRX #XYZ #7246f5a1-a1b4-4ad2-b4d1-b619a42e89ce #coveragefilings #Technology #and

Origin | Interest | Match

OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network OptimizeRx (Nasdaq: OPRX) announced four new partner agreements on Dec. 17, 2025 that expand its point-of-care (POC) network, deepen exclusivity with key platforms, and increase total National Provider Identifier reach. Together the additions and renewals raise OptimizeRx’s unique NPI reach by 37%.Key deals include an exclusive multi-year agreement with a high-demand e-prescribing platform, a new point-of-discharge partnership that extends access when treatment plans are finalized, and multi-year renewals with two top-performing EHR/eRx partners that secure premium inventory and greater visibility into future channel revenue.

#OPRX OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network

www.stocktitan.net/news/OPRX/optimize-rx-co...

News; ( NASDAQ: #OPRX ) PRISM Mid-Day Movers: MedDevice Setback and Healthcare Tech Surge

OptimizeRx Crushes Q2 Earnings: Revenue Up 55%, Swings to Profit, Boosts 2025 Guidance Healthcare tech firm posts 59% gross profit growth, turns $4M loss to $1.5M profit. See raised guidance and accelerated debt reduction details.

#OPRX OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

www.stocktitan.net/news/OPRX/optimize-rx-re...

Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions OptimizeRx (NASDAQ: OPRX) and Simulmedia announced a strategic partnership at Cannes Lions to integrate OptimizeRx's Micro-Neighborhood® Targeting (MNT) technology with Simulmedia's TV and streaming advertising platform. The collaboration enables healthcare brands to target audiences across linear and connected TV using zip-9 geographic disease prevalence mapping while maintaining HIPAA compliance. The partnership allows for rapid deployment of data-driven campaigns, predictive spot-level TV placements, real-time campaign adjustments, and activation across 250+ TV networks. The solution particularly benefits small and mid-size pharmaceutical companies by addressing traditional TV advertising limitations including audience precision, market entry speed, and high minimum spend requirements.

#OPRX Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions

www.stocktitan.net/news/OPRX/simulmedia-and...

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance OptimizeRx (NASDAQ: OPRX) reported strong Q1 2025 financial results with revenue increasing 11% year-over-year to $21.9 million. The company's gross profit grew 9% to $13.3 million, while GAAP net loss improved to $(2.2) million from $(6.9) million in Q1 2024. Non-GAAP net income reached $1.5 million or $0.08 per diluted share.Notably, OptimizeRx has increased its full-year 2025 guidance, projecting revenue between $101-106 million and adjusted EBITDA between $13-15 million. The company's performance metrics show strong momentum, with year-to-date contracted revenue up over 20% compared to last year. Additionally, OptimizeRx has successfully converted over 5% of expected 2025 sales into subscription-based revenue streams.

#OPRX OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

www.stocktitan.net/news/OPRX/optimize-rx-re...

PRISM Watch: Markets Surge on Tariff Truce, But Uncertainty Lingers
Tariff Truce Fuels Global Market Rally
#AAPL, #AMZN, #NVDA, #TSLA, #CSCO, #BABA, #WMT, #TGT, #SGMO, #AMPY, #OPRX, #MODG, #OCX
prismmarketview.com/prism-watch-...

Whetstone Capital Advisors Withdraws Board Nominees Following OptimizeRx Corporation #OPRX Board Refreshment Plans.

To discuss shareholder activism, contact Anu <anu@stockholderdemocracy.com>
#microcaps #stockholderdemocracy #activistinvestor

all messages are opinion | Linktree do not assume accuracy no warranty is implied no liability of any kind exists

Whetstone Capital Advisors Announces Board Nominations for 2025 Annual Meeting at OptimizeRx Corporation #OPRX

#microcap #stockholderdemocracy #activistinvestor
Disclaimer
linktr.ee/disclaimer462

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Wed Mar 12th - #RGLS #SAGE #VIOT #ARMN #DOUG #PFC #OPRX #LENZ #ARTV #IPI #HG #FOA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

BREAKING NEWS: ( NASDAQ: #OPRX ) Expected US Company Earnings on Wednesday, March 12th, 2025

OptimizeRx Doubles Enterprise Deals, Projects $100M Revenue as Subscription Model Takes Off OptimizeRx delivers 29% revenue growth to $92.1M in 2024, doubles enterprise deals, and projects $100M+ for 2025 as it transitions to subscription-based services model.

#OPRX OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/OPRX/optimize-rx-re...

OptimizeRx Faces Board Shakeup as Activist Investor Pushes for Change Whetstone Capital seeks board representation at healthcare tech firm OptimizeRx, nominating two directors for 2025 election. Company reviewing proposals amid governance shift.

#OPRX OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations

www.stocktitan.net/news/OPRX/optimize-rx-co...

OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions for life sciences companies, has scheduled its Fourth Quarter and Full Year 2024 financial results conference call for March 12, 2025, at 8:30 a.m. ET. The company will release its financial results for the quarter ended December 31, 2024, via press release before the conference call. Management will host the call followed by a Q&A session. A replay will be accessible for 12 months through the Investors section of the OptimizeRx website.

#OPRX OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET

www.stocktitan.net/news/OPRX/optimize-rx-se...

#OPRX OptimizeRx to Participate in Upcoming Investor Conferences

www.stocktitan.net/news/OPRX/optimize-rx-to...

#OPRX OptimizeRx Reports Third Quarter 2024 Financial Results

www.stocktitan.net/news/OPRX/optimize-rx-re...